Cited by

• Effects of cisapride on the pancreatic exocrine secretion in rats.

  Funakoshi A, Miyasaka K, Shinozaki H, Kitani K. Funakoshi A, et al. Gastroenterol Jpn. 1988 Oct;23(5):559-63. doi: 10.1007/BF02779489. Gastroenterol Jpn. 1988. PMID: 3215439
• Diabetic gastroparesis. A critical reappraisal of new treatment strategies.

  Drenth JP, Engels LG. Drenth JP, et al. Drugs. 1992 Oct;44(4):537-53. doi: 10.2165/00003495-199244040-00002. Drugs. 1992. PMID: 1281070 Review.
• Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy.

  Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB. Grant SC, et al. Cancer Chemother Pharmacol. 1993;31(6):442-4. doi: 10.1007/BF00685032. Cancer Chemother Pharmacol. 1993. PMID: 8453682
• Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study.

  Davis RH, Clench MH, Mathias JR. Davis RH, et al. Dig Dis Sci. 1988 Dec;33(12):1505-11. doi: 10.1007/BF01535938. Dig Dis Sci. 1988. PMID: 3058442 Clinical Trial.
• Open label study of long-term effectiveness of cisapride in patients with idiopathic gastroparesis.

  Dworkin BM, Rosenthal WS, Casellas AR, Girolomo R, Lebovics E, Freeman S, Clark SB. Dworkin BM, et al. Dig Dis Sci. 1994 Jul;39(7):1395-8. doi: 10.1007/BF02088039. Dig Dis Sci. 1994. PMID: 8026248 Clinical Trial.